Patent Awarded for Axenohl; Milestone Accelerates Marketing and Distribution.Business Editors & Health/Medical Writers SAN DIEGO--(BW HealthWire)--March 8, 2001 Innovative Medical Services (Nasdaq:PURE) today announced that on March 6, 2001, the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property issued US Patent Number 6,197,814 for the unique disinfectant Axenohl and its method of making. The inventor of Axenohl is Andrew B. Arata, and the assignee is NVID NVID Normal Video International Inc. The patent covers one of multiple inventive aspects of the antimicrobial technology. NVID International Inc. has also filed a U.S. Divisional Patent Application A divisional patent application (sometimes referred to as a divisional application or simply a divisional) is a type of patent application which contains matter from a previously-filed application (the "parent" application). to cover other inventive aspects of Axenohl antimicrobial technology. NVID intends to file additional U.S. Divisional Patent Applications on Axenohl in the future. Patent applications have also been filed in more than 50 countries and regions. The Axenohl International Patent Application was published by the World Intellectual Property Organization on April 22, 1999, under publication Number WO 99/18790. "The Axenohl patent is a milestone for Innovative Medical Services," stated Michael L. Krall, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Innovative Medical Services. "Axenohl is a remarkable product with untold potential, and our goal is to bring Axenohl to multiple markets in the U.S. and abroad as quickly as possible. The issuance of the patent allows us to move faster because of the confidence of patent protection and the governmental confirmation of a unique, inventive technology." Innovative Medical Services has worldwide rights to market and manufacture Axenohl. Krall continued, "We would especially like to thank both Mr. Andrew B. Arata, inventor of Axenohl, and the executives of NVID International for their hard work and diligence in obtaining this patent." Axenohl is a revolutionary antimicrobial technology that uses the biocidal bi·o·cid·al adj. Of or relating to an agent that is destructive to living organisms. biocidal (bī´ōsī´d properties of ionic silver to kill bacteria viruses and fungi. Axenohl's broad effectiveness works to prevent and treat infection, and, unlike traditional disinfectants, Axenohl is non-toxic and environmentally friendly. Potential applications for products containing Axenohl include municipal and point-of-use/point-of-entry water treatment, food processing, personal disinfecting retail products, and commercial and retail hard surface disinfecting products. In addition, this technology may prove to be revolutionary in the healthcare market for treatment of disease, including human and animal infections and wounds, and for disinfecting applications in hospitals, clinics, surgical centers, dental offices and other medical and health related facilities. The disinfection disinfection, n the process of destroying pathogenic organisms or rendering them inert. disinfection, full oral cavity, n a procedure used to reduce active periodontal disease, usually completed within a certain short time frame. efficacy of Axenohl has been well documented by independent testing laboratories. Axenohl eliminates the following test organism strains all within one minute and with 99.9999% efficacy (complete kill): Pseudomonas aeruginosa ATCC ATCC American Type Culture Collection, see there 15422, Staphylococcus aureus ATCC 6538, Salmonella cholerasuis ATCC 10708, E. Coli ATCC 0157:H7, Listeria Listeria /Lis·te·ria/ (lis-ter´e-ah) a genus of gram-negative bacteria (family Corynebacterium); L. monocyto´genes causes listeriosis. Lis·te·ri·a n. monocytogenes ATCC 11543, Entrococcus facium ATCC 11543, Rhino virus (common colds), and Rotavirus rotavirus /ro·ta·vi·rus/ (ro´tah-vi?rus) any member of the genus Rotavirus. ro´taviral Rotavirus /Ro·ta·vi·rus/ (ro´tah-vi?rus (infectious diarrhea). About NVID International Inc. NVID International Inc. based in Clearwater, Fla., manufactures and markets patented ionization disinfection technologies that substantially reduce or replace traditional disinfectants such as chlorine or bromine bromine (brō`mēn, –mĭn) [Gr.,=stench], volatile, liquid chemical element; symbol Br; at. no. 35; at. wt. 79.904; m.p. –7.2°C;; b.p. 58.78°C;; sp. gr. of liquid 3.12 at 20°C;; density of vapor 7. . About Innovative Medical Services Innovative Medical Services, based in El Cajon, Calif., is the nation's leader in pharmaceutical water purification. The Company has expanded from its niche pharmacy market into other, broader markets with new products, including residential and commercial water filtration systems, health and wellness-related retail merchandise, silver ion bioscience technologies in addition to the Company's comprehensive e-commerce health supersite, www.Nutripure.com. Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion